Sharing-our-perspective



Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward


  • Missouri enacts opioid prescribing limits

    by
    • Optum
    | Aug 09, 2018
    Tag Icon
    Workers' Compensation, Pain Management, Opioids, Government Affairs
    The Missouri Legislature, in the waning hours of its session, passed legislation containing numerous changes to existing laws governing medical and pharmacy practices. One tucked away segment of the bill imposes prescribing restrictions for initial prescriptions of opioids to treat acute pain.


  • Tennessee enacts enhanced opioid prescribing controls

    by
    • Optum Workers' Comp
    | Jun 01, 2018
    Tag Icon
    Opioids
    House Bill 1831 was recently signed by Tennessee’s Governor, which enacts prescribing restrictions on opioid analgesics; sets dose caps on morphine milligram equivalent (MME); and defines enhanced prescription drug monitoring program (PDMP) requirements. Effective July 1, 2018, the bill bases prescribing restrictions on various treatment timeframes and requires the prescriber to properly examine, justify and document the need for additional opioid treatment.


  • Opioid analgesics have a place in therapy; knowing when and how to use is key

    by
    • Optum Workers' Comp
    | Jul 11, 2017
    Tag Icon
    Workers Comp, Pain Management, Opioids, FDA, Chronic Pain
    The recent agreement between the U.S. Food and Drug Administration (FDA) and Endo Pharmaceuticals to have Opana® ER removed from the U.S. market highlights the ongoing need for awareness on the safety of opioid analgesics and a better understanding of how the medication can affect the major body systems. While this decision resulted from research determining the benefits of using reformulated Opana ER no longer outweigh its risks, the question of whether or not opioid analgesics should continue to have a place in medication therapy remains.


  • Kentucky takes stance on gabapentin to help reduce risk to public health

    by
    • Optum Workers' Comp
    | Jul 07, 2017
    Tag Icon
    Workers Comp, FDA, DEA, Abuse Deterrent
    Kentucky has recently classified all gabapentin products as a Schedule V Controlled Substance to help reduce the risk to public health. This new state regulation, effective July 1, 2017, differs from federal regulations in that the state of Kentucky recognizes the abuse potential of gabapentin.


  • Update to Voluntary recall of Eliquis® (apixaban) 5 mg tablets

    by
    • Optum Workers' Comp
    | Jun 22, 2017
    Tag Icon
    Workers Comp, Eliquis, Medication Recall, FDA
    UPDATE: On June 10, one lot of Eliquis was recalled and designated as a consumer-level recall. On June 17, this recall was changed to a retail/dispensing level only recall. The recall is currently underway at the pharmacy level. As a reminder, patients should not stop taking Eliquis without consulting with their doctor. For more information on this update, click here.




Do you have a question for our
Government Affairs team?






Subscribe
Stay informed by signing up to receive our latest update
*Denotes a required field